These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15832712)

  • 1. [Chronic lymphatic leukemia: primary treatment based on biological risk stratification. Danish Society of Hematology].
    Geisler CH
    Ugeskr Laeger; 2005 Mar; 167(12-13):1392. PubMed ID: 15832712
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
    Brugiatelli M; Bandini G; Barosi G; Lauria F; Liso V; Marchetti M; Mauro FR; Meloni G; Zinzani PL; Tura S; ; ;
    Haematologica; 2006 Dec; 91(12):1662-73. PubMed ID: 17145603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia.
    Gowda A; Byrd JC
    Curr Opin Hematol; 2006 Jul; 13(4):266-72. PubMed ID: 16755224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia.
    Hauswirth AW; Jäger U
    Haematologica; 2008 Jan; 93(1):14-9. PubMed ID: 18166780
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk stratification in chronic lymphocytic leukemia.
    Seiler T; Döhner H; Stilgenbauer S
    Semin Oncol; 2006 Apr; 33(2):186-94. PubMed ID: 16616065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revisiting the role of hematopoietic stem cell transplantation in chronic lymphocytic leukemia.
    Santos ES; Masri M; Safah H
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):875-91. PubMed ID: 16221057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of molecular markers in selecting therapy for CLL.
    Döhner H
    Clin Adv Hematol Oncol; 2005 Feb; 3(2):103-4. PubMed ID: 16166976
    [No Abstract]   [Full Text] [Related]  

  • 8. [Recommendations for the cytogenetic management of chronic lymphocytic leukemia established by the French Group for Cytogenetic Hematology].
    Groupe Français de Cytogénétique Hématologique (GFCH)
    Pathol Biol (Paris); 2004 Jun; 52(5):254-6. PubMed ID: 15217707
    [No Abstract]   [Full Text] [Related]  

  • 9. [Chronic lymphatic leukemia].
    Krusius T
    Duodecim; 1989; 105(11):1077-87. PubMed ID: 2666091
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Ilaria Del Principe M; Buccisano F; Maurillo L; Niscola P; Venditti A; Amadori S
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1787-800. PubMed ID: 17181492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developments in the treatment of lymphoproliferative disorders: rising to the new challenges of CLL therapy. A report of a symposium presented during the 48th American Society of Hematology Annual Meeting and Exposition, December 8, 2006, Orlando, Florida.
    Clin Adv Hematol Oncol; 2007 Mar; 5(3 Suppl 5):1-14; quiz 15-6. PubMed ID: 17519887
    [No Abstract]   [Full Text] [Related]  

  • 12. Emerging therapy for chronic lymphocytic leukaemia.
    Auer RL; Gribben J; Cotter FE
    Br J Haematol; 2007 Dec; 139(5):635-44. PubMed ID: 17961187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic factors in chronic lymphocytic leukaemia: contribution of recent biological markers].
    Evrard S; Gaussem P; Helley D; Darnige L
    Ann Biol Clin (Paris); 2005; 63(6):589-97. PubMed ID: 16330377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune complications of B-cell chronic lymphatic leukaemia.
    Travers J; Leach M; Jackson R
    Br J Haematol; 2004 Jul; 126(1):2. PubMed ID: 15198726
    [No Abstract]   [Full Text] [Related]  

  • 15. Danish CLL2-Study revisited: FISH on a cohort with a 20-yr follow-up confirms the validity of the hierarchical model of genomic aberrations in chronic lymphocytic leukaemia.
    Geisler C; Jurlander J; Bullinger L; Sander S; Brown P; Benner A; Philip P; Döhner H; Stilgenbauer S;
    Eur J Haematol; 2009 Aug; 83(2):156-8. PubMed ID: 19302558
    [No Abstract]   [Full Text] [Related]  

  • 16. Chronic lymphocytic leukemia--aiming at a moving target!
    Hillmen P
    Haematologica; 2005 Nov; 90(11):1451-2. PubMed ID: 16266890
    [No Abstract]   [Full Text] [Related]  

  • 17. Chronic lymphocytic leukemia: recent advances in diagnosis and treatment.
    Abbott BL
    Oncologist; 2006 Jan; 11(1):21-30. PubMed ID: 16401710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies in chronic lymphocytic leukemia.
    Ferrajoli A; Faderl S; Keating MJ
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1231-8. PubMed ID: 17020457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updates in CLL: prognostic markers and their implication for treatment strategies.
    Clin Adv Hematol Oncol; 2007 Apr; 5(4 Suppl 7):4-14; quiz 15-6. PubMed ID: 17637593
    [No Abstract]   [Full Text] [Related]  

  • 20. [Chronic lymphatic leukemia. Prognosis and effects of treatment in 170 patients during the period 1976-1986].
    Johnsen HE; Bergmann OJ; Boesen AM; Segel E; Kristensen JS; Bastrup-Madsen P; Ellegaard J
    Ugeskr Laeger; 1988 Nov; 150(45):2735-9. PubMed ID: 3206673
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.